Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Granisetron controlled-release - Heron Therapeutics

Next Previous
Drug Profile

Granisetron controlled-release - Heron Therapeutics

Alternative Names: APF-530; Sustol

Latest Information Update: 15 May 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator A.P. Pharma
  • Developer Heron Therapeutics
  • Class Analgesics; Antiemetics; Azabicyclo compounds; Indazoles; Small molecules
  • Mechanism of Action Serotonin 3 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Chemotherapy-induced nausea and vomiting

Most Recent Events

  • 31 Dec 2024 Heron Therapeutics has patent protection for Sustol in France, Germany, Hong Kong, Ireland, Italy, Japan, Spain, Sweden, Switzerland, Taiwan, United Kingdom
  • 30 Sep 2020 Heron Therapeutics withdraws phase II trial for Chemotherapy-induced nausea and vomiting (In adults, Prevention) prior to enrolment in USA (SC, Extended release) in September 2020 (NCT04085393)
  • 31 Oct 2016 Launched for Chemotherapy induced nausea and vomiting (Combination therapy, Prevention) in USA (SC) (First global launch) before October 2016

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top